Host Blood Transcriptional Signatures as Candidate Biomarkers for Predicting Progression to Active Tuberculosis

A recent understanding of the dynamic continuous spectrum of Mycobacterium tuberculosis infection has led to the recognition of incipient tuberculosis, which refers to the latent infection state that has begun to progress to active tuberculosis. The importance of early detection of these individuals with a high-risk of progression to active tuberculosis is emphasized to efficiently implement targeted tuberculosis preventive therapy. However, the tuberculin skin test or interferon-γ release assay, which is currently used for the diagnosis of latent tuberculosis infection, does not aid in the prediction of the risk of progression to active tuberculosis. Thus, a novel test is urgently needed. Recently, simultaneous and systematic analysis of differentially expressed genes using a high-throughput platform has enabled the discovery of key genes that may serve potential biomarkers for the diagnosis or prognosis of diseases. This host transcriptional investigation has been extended to the field of tuberculosis, providing promising results. The present review focuses on recent progress and challenges in the field of blood transcriptional signatures to predict progression to active tuberculosis.

[1]  S. Krishnan,et al.  Are mRNA based transcriptomic signatures ready for diagnosing tuberculosis in the clinic? - A review of evidence and the technological landscape , 2022, EBioMedicine.

[2]  A. Fiore-Gartland,et al.  Prospective multicentre head-to-head validation of host blood transcriptomic biomarkers for pulmonary tuberculosis by real-time PCR , 2022, Communications Medicine.

[3]  R. Long,et al.  THE RADIOGRAPHIC AND MYCOBACTERIOLOGIC CORRELATES OF SUBCLINICAL PULMONARY TUBERCULOSIS IN CANADA: A RETROSPECTIVE COHORT STUDY. , 2022, Chest.

[4]  H. Kuivaniemi,et al.  Diagnostic Accuracy of the Cepheid 3-gene Host Response Fingerstick Blood Test in a Prospective, Multi-site Study: Interim Results , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  Richard G. White,et al.  Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy study , 2021, The Lancet. Global health.

[6]  Richard G. White,et al.  Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial , 2021, The Lancet. Infectious diseases.

[7]  Mark M. Davis,et al.  Antigen-Specific T-Cell Activation Distinguishes between Recent and Remote Tuberculosis Infection , 2021, American journal of respiratory and critical care medicine.

[8]  Richard G. White,et al.  Potential population level impact on tuberculosis incidence of using an mRNA expression signature correlate-of-risk test to target tuberculosis preventive therapy , 2019, Scientific Reports.

[9]  Carolin T. Turner,et al.  Concise whole blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-level pooled meta-analysis , 2019, bioRxiv.

[10]  B. Chain,et al.  Blood transcriptomic stratification of short-term risk in contacts of tuberculosis. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  R. Wilkinson,et al.  The value of transcriptomics in advancing knowledge of the immune response and diagnosis in tuberculosis , 2018, Nature Immunology.

[12]  J. Deeks,et al.  Prognostic value of interferon-γ release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study , 2019 .

[13]  D. Sherman,et al.  Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection , 2018, Clinical Microbiology Reviews.

[14]  Alimuddin Zumla,et al.  Tuberculosis: advances and challenges in development of new diagnostics and biomarkers. , 2018, The Lancet. Infectious diseases.

[15]  S. Fortune,et al.  Immunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection , 2018, Nature Reviews Immunology.

[16]  C. Denkinger,et al.  Diagnostic Test for Incipient Tuberculosis: A Step Forward, Many More to Go. , 2018, American journal of respiratory and critical care medicine.

[17]  Daniel E. Zak,et al.  Four‐Gene Pan‐African Blood Signature Predicts Progression to Tuberculosis , 2018, American journal of respiratory and critical care medicine.

[18]  M. Kaforou,et al.  Genome‐wide host RNA signatures of infectious diseases: discovery and clinical translation , 2017, Immunology.

[19]  Antonio Federico,et al.  Transcriptome Profiling in Human Diseases: New Advances and Perspectives , 2017, International journal of molecular sciences.

[20]  A. Lalvani,et al.  Stratification of Latent Mycobacterium tuberculosis Infection by Cellular Immune Profiling , 2017, The Journal of infectious diseases.

[21]  T. Ottenhoff,et al.  Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis , 2016, European Respiratory Journal.

[22]  Peter J Dodd,et al.  The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling , 2016, PLoS medicine.

[23]  J. Flynn,et al.  Characterization of progressive HIV-associated tuberculosis using 2-deoxy-2-[18F]fluoro-D-glucose positron emission and computed tomography , 2016, Nature Medicine.

[24]  Daniel E. Zak,et al.  A prospective blood RNA signature for tuberculosis disease risk , 2016, The Lancet.

[25]  B. Hauer,et al.  Advancing global programmatic management of latent tuberculosis infection for at risk populations , 2016, European Respiratory Journal.

[26]  Purvesh Khatri,et al.  Genome-wide expression for diagnosis of pulmonary tuberculosis: a multicohort analysis. , 2016, The Lancet. Respiratory medicine.

[27]  R. Chaisson,et al.  Latent Mycobacterium tuberculosis infection. , 2015, The New England journal of medicine.

[28]  R. Duarte,et al.  Risk Assessment of Tuberculosis in Contacts by IFN-γ Release Assays. A Tuberculosis Network European Trials Group Study. , 2015, American journal of respiratory and critical care medicine.

[29]  A. O’Garra,et al.  The application of transcriptional blood signatures to enhance our understanding of the host response to infection: the example of tuberculosis , 2014, Philosophical Transactions of the Royal Society B: Biological Sciences.

[30]  R. Wilkinson,et al.  The ongoing challenge of latent tuberculosis , 2014, Philosophical Transactions of the Royal Society B: Biological Sciences.

[31]  L. Coin,et al.  Diagnosis of childhood tuberculosis and host RNA expression in Africa. , 2014, The New England journal of medicine.

[32]  K. Holt,et al.  Out-of-Africa migration and Neolithic co-expansion of Mycobacterium tuberculosis with modern humans , 2013, Nature Genetics.

[33]  M. Amicosante,et al.  Antigen-specific CD4- and CD8-positive signatures in different phases of Mycobacterium tuberculosis infection. , 2013, Diagnostic microbiology and infectious disease.

[34]  R. Diel,et al.  Predictive value of interferon-γ release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. , 2012, Chest.

[35]  V. Pascual,et al.  Assessing the human immune system through blood transcriptomics , 2010, BMC Biology.

[36]  JoAnne L. Flynn,et al.  Understanding Latent Tuberculosis: A Moving Target , 2010, The Journal of Immunology.

[37]  Virginia Pascual,et al.  An Interferon-Inducible Neutrophil-Driven Blood Transcriptional Signature in Human Tuberculosis , 2010, Nature.

[38]  J. Flynn,et al.  The spectrum of latent tuberculosis: rethinking the biology and intervention strategies , 2009, Nature Reviews Microbiology.

[39]  F. Cobelens,et al.  LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement , 2009, European Respiratory Journal.

[40]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[41]  C. Dye,et al.  Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. , 1999, JAMA.